Orthotopic Patient-Derived Xenografts of Pediatric Solid Tumors

[1]  Heather L. Mulder,et al.  Targeting oxidative stress in embryonal rhabdomyosarcoma. , 2013, Cancer cell.

[2]  Li Ding,et al.  Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. , 2014, Cancer discovery.

[3]  A. Villanueva,et al.  Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments , 2016, Clinical and Translational Oncology.

[4]  P. Atadja,et al.  In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma , 2010, Haematologica.

[5]  M. Spector,et al.  Organoid Models of Human and Mouse Ductal Pancreatic Cancer , 2015, Cell.

[6]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[7]  Jens C. Streibig,et al.  Bioassay analysis using R , 2005 .

[8]  P. Atadja.  Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. , 2009, Cancer letters.

[9]  John W. Cassidy,et al.  A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds , 2016, Cell.

[10]  I. Campbell.  Chi‐squared and Fisher–Irwin tests of two‐by‐two tables with small sample recommendations , 2007, Statistics in medicine.

[11]  Donna Neuberg,et al.  The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. , 2016, Cancer cell.

[12]  A. Sweet-Cordero,et al.  Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer. , 2015, Cancer research.

[13]  R. Neuwirth,et al.  Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma , 2010, Cancer Chemotherapy and Pharmacology.

[14]  S. Altekruse,et al.  Declining childhood and adolescent cancer mortality , 2014, Cancer.

[15]  John T. E. Richardson.  The analysis of 2 × 2 contingency tables—Yet again , 2011, Statistics in medicine.

[16]  B. Liederer,et al.  Evaluation of homogenization techniques for the preparation of mouse tissue samples to support drug discovery. , 2011, Bioanalysis.

[17]  J. Doroshow,et al.  Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Sorger,et al.  Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs , 2016, Nature Methods.

[19]  Hans Clevers,et al.  Organoid Cultures Derived from Patients with Advanced Prostate Cancer , 2014, Cell.

[20]  Li Ding,et al.  Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. , 2014, Cell reports.

[21]  Hayley E. Francies,et al.  Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients , 2015, Cell.

[22]  A. Pappo,et al.  Pediatric solid tumor genomics and developmental pliancy , 2015, Oncogene.

[23]  Abbas Shirinifard,et al.  Targeting the DNA repair pathway in Ewing sarcoma. , 2014, Cell reports.

[24]  Donna Neuberg,et al.  The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. , 2016, Cancer cell.

[25]  Sara M. Federico,et al.  The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities. , 2016, Developmental biology.

[26]  Manolis Kellis,et al.  ChromHMM: automating chromatin-state discovery and characterization , 2012, Nature Methods.

[27]  Christopher A. Miller,et al.  Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. , 2014, Cancer cell.

[28]  J. T. Caldwell,et al.  Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 , 2013, PloS one.

[29]  Heather L. Mulder,et al.  Genomic landscape of paediatric adrenocortical tumours , 2016 .

[30]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .